{
    "clinical_study": {
        "@rank": "21556", 
        "arm_group": [
            {
                "arm_group_label": "Breast-fed infants", 
                "description": "80 infants of mothers who plan to exclusively breastfeed for at least 6 months."
            }, 
            {
                "arm_group_label": "Formula-fed infants", 
                "description": "Mother is exclusively feeding infant formula milk less than or equal to 6 weeks of birth and has no prospect of breastfeeding.\nMother consents to her infant receiving trial infant formula for 12 months"
            }
        ], 
        "biospec_descr": {
            "textblock": "Faecal samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Prospective cohort study of breast and formula fed infants in a suburban setting in Jakarta,\n      Indonesia"
        }, 
        "brief_title": "The Growth and Development of Breast and Formula Fed Term Asian Infants", 
        "completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "condition": "Growth", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Breast-fed: 1. Mother intends to exclusively breast-feed from birth to at least 4\n             months; 2. A healthy term infant with gestational age fo 37-42 weeks and birth weight\n             greater than or equal to 2.5 kg and equal or less than 4.75 kg.\n\n          -  Formula-fed: 1. Mother is exclusively feeding infant formula milk less than or equal\n             to 6 weeks of birth and has no prospect of breastfeeding; 2. A healthy term infant\n             with gestational age fo 37-42 weeks and birth weight greater than or equal to 2.5 kg\n             and equal or less than 4.75 kg; 3. Mother consents to her infant receiving trial\n             infant formula for 12 months.\n\n        Exclusion Criteria:\n\n          -  1. Severe congenital or metabolic disease likely to affect infant feeding or infant\n             growth.\n\n          -  2. Multiple birth"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "6 Weeks", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Healthy infants recruited from Jati Padang, Pasar Minggu District, South Jakarta,\n        Indonesia"
            }
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 1, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01721512", 
            "org_study_id": "Project Grow"
        }, 
        "intervention": [
            {
                "arm_group_label": "Breast-fed infants", 
                "intervention_name": "Breastfeeding", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Formula-fed infants", 
                "intervention_name": "Infant formula", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prospective observational study", 
            "Breast feeding", 
            "Infant formula", 
            "Infant", 
            "Indonesia"
        ], 
        "lastchanged_date": "November 2, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Jakarta", 
                    "country": "Indonesia", 
                    "zip": "10430"
                }, 
                "name": "Universitas Indonesia"
            }
        }, 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_groups": "2", 
        "official_title": "The Growth and Development of Breast and Formula Fed (Containing Synbiotics and LCPUFA) Term Asian Infants.", 
        "overall_official": {
            "affiliation": "Indonesia University", 
            "last_name": "Agus Firmansyah, Professor, MD, PhD, SpA(K)", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Fonterra Maternal and Pediatric Advisory Board, New Zealand':'", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Infant weight, body length head circumference at enrolment, 2 weeks, 4 weeks and monthly thereafter until 6 months, and then at 8, 10 and 12 months.", 
            "measure": "Infant weight, body length head circumference", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01721512"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Indonesia University", 
            "investigator_full_name": "Prof.  Agus Firmansyah, MD, Ph.D", 
            "investigator_title": "Professor and Chief, Division of Gastrohepatology, Department of Child Health, Medical Faculty, University of Indonesia", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Gastrointestinal tolerance: stool frequency and consistency using Bristol Stool Chart monthly up to 6 months", 
                "measure": "Gastrointestinal tolerance", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Indicators or formula tolerance: crying, irritability, sleep patterns", 
                "measure": "Indicators or formula tolerance", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "General health: any hospitalisation, doctor visits, symptoms of respiratory or gastrointestinal infection, fever, antibiotic and medication usage", 
                "measure": "General health", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Gut integrity: faecal Alpha1-antitrypsin and faecal calprotectin", 
                "measure": "Gut integrity", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Gut microflora: real time PCR", 
                "measure": "Gut microflora", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Developmental progress: assessed by Ages and Stages", 
                "measure": "Developmental progress", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Indonesia University", 
        "sponsors": {
            "collaborator": {
                "agency": "Fonterra Brands (Singapore) PTE LTD", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Indonesia University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2012"
    }
}